HealthTechX Summit

Sokratis Papafloratos is CEO and founder of Numan.Sokratis founded Numan in 2018, with a vision of building a digital health company that could help people live happier, healthier, and longer lives. As CEO, he has raised $153 million in funding and built a team of over 400 people, with operations in London, Cardiff and Greece. The team have helped over 650,000 patients with health issues ranging from obesity management to testosterone deficiency and hair loss.Prior to Numan, Sokratis was a serial entrepreneur and investor, backing some of Britain’s best start-up tech businesses, and founding three of his own. He was one of the first investors in the award-winning Calm.com mindfulness app, as well as Secret Escapes, one of the world’s leading members-only travel companies. Sokratis founded his first company in 2006: the UK’s earliest local reviews site, TrustedPlaces, which was then acquired by Yell Group. 

Roberta Ferrari is a Managing Director in the EQT Life Sciences team. Prior to joining EQT Life Sciences team, Roberta worked for 10 years as a Senior Investment Manager at Sony Innovation Fund in London, UK looking after digital health investments across EU and Middle East. Prior to Sony, Roberta was a Senior Consultant at Deloitte in Milan, Italy.

Roberta holds a MSc (Hons) and BSc In Industrial and Managerial Engineering, both from the University of Brescia (Italy). Roberta also studied Managerial Finance at the LSE and Venture Capital Programme at University of Oxford, UK.

Digital executive, entrepreneur, and private equity investor, Ranjan has been innovating and investing in sectors on the cusp of transformation for over 25 years. Ranjan co-founded HealthHero in 2019, quickly growing it to become the European leader in digital telehealth. HealthHero connects smart technology and gold-standard clinical expertise to make high-quality healthcare accessible to millions. 

Mark Slack qualified as a doctor at the University of the Witwatersrand in South Africa. He then completed his postgraduate training at the University of Cape Town. He graduated from the College of Medicine of South Africa in Gynaecology, winning the Daubenton Gold Medal for the most distinguished candidate in the exams in the country.

He was previously head of Gynaecology and Urogynaecology at Addenbrooke’s Hospital, University of Cambridge Teaching Hospitals Trust, Cambridge. He is an honorary Lecturer at the University of Cambridge.

Mr Slack has run an active research unit in Cambridge which was involved in a number of research initiatives. While still a registrar he developed, introduced and published on the Sacrospinous Fixation. This was a first in the UK and is now the most performed procedure for uterovaginal prolapse in the United Kingdom. In addition, he has invented several procedures which were adopted and taken to global launch by Johnson & Johnson. He has published over 100 peer reviewed papers, more than 25 book chapters and numerous national guidelines. He is a regular contributor on several National Radio and Television programs including “Case notes”, “Women’s Hour”, The Victoria Derbyshire show and regional and national news programs.

In 1996, Mr Slack identified the use of artificial mesh to be potentially hazardous in surgery for prolapse and incontinence. Following basic science studies, he published a classification of the different types highlighting that many products on sale were not safe for human use. He was a contributor to the Cumberledge commission and an expert witness in many of the class actions in the United States. He published an algorithm for the management of mesh cases which has been adopted internationally.

He is a Co-founder and Chief Medical Officer of CMR Surgical, a start-up company in Cambridge which has developed a novel surgical robot (Versius). This is a next generation surgical robotic system designed to increase the use of minimally invasive (keyhole) surgery. From starting the company in 2014, it is now the second largest soft tissue robotic company in the world. In 2021, it had the highest private MedTech funding round in the world with a $660 million raise. The subsequent valuation gave it Unicorn status. The company currently employs more than 700 people in multiple geographies. In 2023, it raised a further £165 million. Mr Slack has developed an advanced training program for the robot which is now accredited by the Royal College of Surgeons of England. It utilises VR headsets and training on mannikins to reduce cost.

He has published on A.I. and data solutions for surgical safety, and has developed a registry to monitor the outcomes of the robotic program. He publishes actively on the science behind using registries for surgical safety.

Mr Slack was appointed the Ethicon travelling Professor in 2004 as well as the Sims Black Professorship of the Royal College of Obstetricians and Gynaecologists for 2005/6. He was recognised by the NIHR in 2015 with an award as one of the leading researchers in the UK for clinical research. In 2018, under his leadership, the Urogynaecology unit in Cambridge achieved the highest accreditation score ever awarded by the Royal College of Obstetricians and Gynaecologists, recognising it as one of the leading units in the country. In 2021, he was awarded an honorary fellowship of the Royal College of Surgeons and Physicians of Glasgow and the French Academy of Surgeons. More recently he has been awarded an honorary Fellowship by the Royal College of Surgeons of England and a Lifetime Achievement Award by the British Society of Urogynaecology. This is only the 5^th time it has been awarded in 25 years.

Adam Hunter is the CEO and a founding member of Phlo Technologies Ltd, one of the UK’s leading digital healthcare providers.

Since launching the business in 2020, Adam has led Phlo from inception to an 8-figure revenue scale-up, shaping the future of digital healthcare across the UK.

Under Adam’s leadership, Phlo has developed and expanded several innovative platforms, including:

• Phlo Clinic – a direct-to-consumer digital healthcare platform
• Phlo Connect – a B2B2C digital infrastructure solution powering prescribing, dispensing, and delivery for healthcare providers and digital health brands.
• Phlo Digital Pharmacy – The UK’s first digital pharmacy offering a same-day prescription delivery service for NHS patients.
  
  

With experience spanning D2C, B2B, and B2B2C models, Adam offers a practical perspective on what it takes to scale and succeed in today’s rapidly evolving health consumer economy.

At HealthTechX 2025, Adam will share his firsthand experience of building patient-led healthtech platforms and what it takes to thrive in the evolving consumer health landscape.

Gabriele leads XTX Ventures at XTX Markets. XTX Markets is an algorithmic market maker harnessing the power of machine learning. XTX Ventures focuses on late seed to series A fundraises of ML/AI-driven software and deeptech businesses. Portfolio to date includes Anthropic, Groq, Tenstorrent, Oriole Networks, Gladia, Qureight, Turbine and many other AI success stories.